{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:37:19Z","timestamp":1791434239426,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102654","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:58:54Z","timestamp":1787641134000},"page":"102654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis)"],"prefix":"10.1016","author":[{"given":"Anna Amela","family":"Valsecchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-9053","authenticated-orcid":false,"given":"Lucia","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Bozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1184-6426","authenticated-orcid":false,"given":"Emilia","family":"Cocorocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Dalla","family":"Volta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Maria","family":"Deppieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-9022","authenticated-orcid":false,"given":"Andrea","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-0567","authenticated-orcid":false,"given":"Martina","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Fantinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-301X","authenticated-orcid":false,"given":"Arianna","family":"Dri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-7687","authenticated-orcid":false,"given":"Roberto","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6008-0266","authenticated-orcid":false,"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Icardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"La Russa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0347-9179","authenticated-orcid":false,"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Maines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Masini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-2269","authenticated-orcid":false,"given":"Cecilia","family":"Nasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-0196","authenticated-orcid":false,"given":"Francesco","family":"Pierantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5814-2296","authenticated-orcid":false,"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-7755","authenticated-orcid":false,"given":"Mariella","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3258-5471","authenticated-orcid":false,"given":"Luca","family":"Tondulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9756-6112","authenticated-orcid":false,"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-0292","authenticated-orcid":false,"given":"Francesca","family":"Vignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8551-266X","authenticated-orcid":false,"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Andrea","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10451","key":"10.1016\/j.clgc.2026.102654_bib0001","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.clgc.2026.102654_bib0002","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2026.102654_bib0003","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102654_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.clgc.2026.102654_bib0005","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102654_bib0006","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102654_bib0007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102654_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103881","article-title":"Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors","volume":"181","author":"Delcuratolo","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2026.102654_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102295","article-title":"Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis","volume":"100","author":"Ciccarese","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2026.102654_bib0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2020.05.009","article-title":"Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma","volume":"135","author":"McGregor","year":"2020","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2026.102654_bib0011","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102654_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060987","article-title":"Bone metastasis from renal cell carcinoma","volume":"17","author":"Chen","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.clgc.2026.102654_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-015-0122-0","article-title":"Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?","volume":"34","author":"Santoni","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102654_bib0014","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1186\/s12891-025-09021-z","article-title":"The prognostic role of key factors in renal cell carcinoma with bone metastases","volume":"26","author":"Erdo\u011fan","year":"2025","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clgc.2026.102654_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211019642","article-title":"Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)","volume":"13","author":"Rebuzzi","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102654_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100634","article-title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","volume":"7","author":"Rebuzzi","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.clgc.2026.102654_bib0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15586\/jkcvhl.v12i4.403","article-title":"Meet-URO score validation in real-world patients with metastatic renal cell carcinoma receiving first-line pembrolizumab plus axitinib: a subanalysis of the prospective ProPAXI study","volume":"12","author":"Air\u00f2","year":"2025","journal-title":"J Kidney Cancer VHL"},{"issue":"18","key":"10.1016\/j.clgc.2026.102654_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14186385","article-title":"Evaluation of the Meet-URO score in a real-world cohort of mRCC patients treated with first-line TKIs","volume":"14","author":"\u00d6zalp","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.clgc.2026.102654_bib0019","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clgc.2023.10.001","article-title":"Prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: a subanalysis of the prospective ZEBRA study (Meet-URO 9)","volume":"22","author":"Damassi","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102654_bib0020","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.juro.2010.12.037","article-title":"Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?","volume":"185","author":"Kume","year":"2011","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102654_bib0021","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/COC.0b013e3181574084","article-title":"Sorafenib for metastatic renal cancer: the Princess Margaret experience","volume":"31","author":"Riechelmann","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2026.102654_bib0022","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.7150\/jca.113258","article-title":"Tyrosine kinase inhibitors outperform immune checkpoint inhibitors in bone-predominant metastatic renal cell carcinoma: a multicenter real-world analysis","volume":"16","author":"Meng","year":"2025","journal-title":"J Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2026.102654_bib0023","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41585-018-0034-9","article-title":"An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma","volume":"15","author":"Gr\u00fcnwald","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102654_bib0024","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jvir.2012.03.002","article-title":"Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation","volume":"23","author":"Bang","year":"2012","journal-title":"J Vasc Interv Radiol"},{"issue":"16_Suppl","key":"10.1016\/j.clgc.2026.102654_bib0025","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2025.43.16_suppl.4505","article-title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis from the phase 3 CheckMate 214 trial","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clgc.2026.102654_bib0026","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102654_bib0027","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18 Pt 2","key":"10.1016\/j.clgc.2026.102654_bib0028","doi-asserted-by":"crossref","first-page":"6397s","DOI":"10.1158\/1078-0432.CCR-040030","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"Lipton","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.clgc.2026.102654_bib0029","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2012.02.050","article-title":"Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma","volume":"48","author":"Keizman","year":"2012","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2026.102654_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clgc.2026.102654_bib0031","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102654_bib0032","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1186\/s12885-024-12319-1","article-title":"International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma\u2014meet-URO 33 study (REGAL study)","volume":"24","author":"Rebuzzi","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102654_bib0033","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.clgc.2017.01.010","article-title":"Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era","volume":"15","author":"Kalra","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102654_bib0034","series-title":"Poster presented at: 2022 European Society for Medical Oncology; September 9-13","article-title":"Patterns of care and outcomes of metastatic renal cell carcinoma (mRCC) patients with bone metastases: a UK multicenter review","author":"Challapalli","year":"2022"},{"key":"10.1016\/j.clgc.2026.102654_bib0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.10.023","article-title":"Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer centre","volume":"107","author":"Ruatta","year":"2019","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2026.102654_bib0036","first-page":"7047","article-title":"One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)","volume":"30","author":"Fusco","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102654_bib0037","first-page":"202","article-title":"Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects","volume":"32","author":"Fusco","year":"2024","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102654_bib0038","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/03008916251363754","article-title":"Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs \u00b1 IO and bone agents: a real-world analysis","volume":"111","author":"Stellato","year":"2025","journal-title":"Tumori"},{"key":"10.1016\/j.clgc.2026.102654_bib0039","unstructured":"AIOM. Linee guida metastasi ossee e salute dell'osso. Available at https:\/\/www.aiom.it\/linee-guida-aiom-2024-metastasi-ossee-e-salute-dellosso\/ Accessed September 11, 2026"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:49:20Z","timestamp":1789764560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"alternative-id":["S1558767326001540"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102654","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102654"}}